The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

The invention relates to a method for producing, amongst other things, amino-acid and/or hydroxycarboxylic-acid metal chelates, a solvent-free mixture of at least one metal oxide, metal hydroxide, metal carbonate or oxalate, and the solid organic acid is subjected to intensive mechanical stress. According to the invention, this is done in that the reaction partners are introduced in particle form into a fluid stream of a fluid-bed countercurrent mill operating without grinding elements, wherein mechanical activation of at least one of the reaction partners is effected by collision processes within a reaction chamber formed in a region of the fluid stream, and a solid body reaction to form the metal chelate is triggered. The novel method operates very energy-efficiently and with a high specific yield. It leads to a product having compact particles in the small, single-digit micrometer range having a comparatively narrow particle size distribution and a large surface. The product is homogenous and very pure. Thermal loading or decomposition of the organic chelate ligands, in particular of the amino acids, is likewise avoided, as are contaminants from milling and grinding element abrasion.

The invention relates to a method for producing, amongst other things, amino-acid and/or hydroxycarboxylic-acid metal chelates, a solvent-free mixture of at least one metal oxide, metal hydroxide, metal carbonate or oxalate, and the solid organic acid is subjected to intensive mechanical stress. According to the invention, this is done in that the reaction partners are introduced in particle form into a fluid stream of a fluid-bed countercurrent mill operating without grinding elements, wherein mechanical activation of at least one of the reaction partners is effected by collision processes within a reaction chamber formed in a region of the fluid stream, and a solid body reaction to form the metal chelate is triggered. The novel method operates very energy-efficiently and with a high specific yield. It leads to a product having compact particles in the small, single-digit micrometer range having a comparatively narrow particle size distribution and a large surface. The product is homogenous and very pure. Thermal loading or decomposition of the organic chelate ligands, in particular of the amino acids, is likewise avoided, as are contaminants from milling and grinding element abrasion.

The application provides nutraceutical compositions supporting an active life style. In one embodiment, the nutraceutical composition includes a gelling component in a sufficient amount to provide a cohesive gelled product and an active component. The active component consists of a vitamin B composition, a carbohydrate composition, a stimulant composition, a mineral composition, an antioxidant composition, and an herbal composition.

The application provides nutraceutical compositions supporting mental alertness. In one embodiment, the nutraceutical composition comprises an active component and a gelling component in a sufficient amount to provide a cohesive gelled product. The active component comprises a carbohydrate composition, a vitamin B composition, a caffeinated composition and an anxiolytic composition, wherein the carbohydrate composition comprises a high glycemic index (GI) sugar having a GI not less than 70.

The application provides nutraceutical compositions supporting mental alertness. In one embodiment, the nutraceutical composition comprises an active component and a gelling component in a sufficient amount to provide a cohesive gelled product. The active component comprises a carbohydrate composition, a vitamin B composition, a caffeinated composition and an anxiolytic composition, wherein the carbohydrate composition comprises a high glycemic index (GI) sugar having a GI not less than 70.

A stable zinc polyglutamic acid complex well soluble in water was prepared by conjugating zinc to polyglutamic acid, and then was made into a capsule or injection formulation. It was verified that such a substance not only acts as a zinc supplier necessary for our bodies but also shows an anticancer effect on cancer cells and an alleviating effect on pollinosis caused from the stimulation of mucous membrane by pollen. Therefore, the purpose of the present invention is to prepare and provide a composition usable in humans, animals, and plants.

A stable zinc polyglutamic acid complex well soluble in water was prepared by conjugating zinc to polyglutamic acid, and then was made into a capsule or injection formulation. It was verified that such a substance not only acts as a zinc supplier necessary for our bodies but also shows an anticancer effect on cancer cells and an alleviating effect on pollinosis caused from the stimulation of mucous membrane by pollen. Therefore, the purpose of the present invention is to prepare and provide a composition usable in humans, animals, and plants.

The present invention relates to a formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies containing a triazinone such as toltrazuril and a polynuclear iron(III) polysaccharide complex compound together with a specifically selected surfactant that has a hydrophilic-lipophilic-balance (HLB) value of ≥10.

Formulations containing triazinones, selected from toltrazuril, ponazuril and diclazuril, a polynuclear iron(III) polysaccharide complex compound which are suitable for the simultaneous control of coccidiosis and anaemic states in animals and which exhibit a low amount of free iron ions even after storage, while the formulations comprises Ca.sup.2+ and Na.sup.+ in a molar ratio of Ca.sup.2+:Na.sup.+ from ≥0 to ≤3. In one embodiment the triazinone is toltrazuril and the polynuclear iron(III) polysaccharide complex compound is iron(III) dextran glucoheptonate.